J Korean Med Assoc.  2003 Dec;46(12):1071-1096. 10.5124/jkma.2003.46.12.1071.

Practice Guidelines for the Manegement of Alzheimer's Disease

• Park JH
• Oh BH
• Yeon BK
• Han SH
• Han IW
• Suh GH
• Kim S
• Bae JN
• Chong JH
• Lee JH

• KMID: 2183140
• DOI: http://doi.org/10.5124/jkma.2003.46.12.1071

Abstract

No abstract available.

MeSH Terms

Alzheimer Disease*

Reference

1. California Workgroup on guidelines for Alzheimer's disease management. Guidelines of Alzheimer's disease management. 2002.

2. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry. 1997. 154:1–39.

3. American Academy of Neurology. Practice parameter : Management of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2001.

4. National Institute of Clinical Excellence. Guidance on the use of Donepezil. Rivastigmine and Galantamine. 2001.

5. Qizilbash N, Schneider NS, Chui H, Tariot P, Brodaty M, Kaye J, et al. Evidence-based Dementia Practice. 2002. Malden: Blackwell Science Ltd.

6. Maj M, Sartorius N. Dementia, WPA Series Evidence and Experience in Psychiatry. 2000. Wiley.

7. Richter RW, Richter BZ. Alzheimer's Disease. 2002. Mosby.

8. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye HA, Guyther L, et al. Practice parameter:management of dementia (an evidence-based review). Neurology. 2001. 56:1154–1166.

9. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease:a review of progress. J Neurol Neurosurg Psychiatry. 1999. 66:137–147.

10. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State" : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975. 12:189–198.

11. Park JH, Kwon YC. Modification of the Mini-Mental State Examination for use in the elderly in a non-western society. Part I. Development of Korean version of Mini-Mental State Examination. Int J Geriatr Psychiatry. 1990. 5:381–387.

12. Park JH, Park YN, Ko HJ. Modification of the Mini-Mental State Examination for use in the elderly in a non-western society. Part II. Cutoff points and their diagnostic validities. Int J Geriatr Psychiatry. 1991. 6:875–882.

13. Giacobini E. Selective inhibitors of butyrylcholinesterase:a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001. 18:891–898.

14. Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Mobius HJ, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl. 2002. 135–148.

15. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001. 57:613–620.

16. Peskind ER. Pharmacologic approaches to cognitive deficits in Alzheimer's disease. J Clin Psychiatry. 1998. 59:Suppl 9. 22–27.

17. Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S. Galantamine provides broad benefits in patients with advanced moderate Alzheimer's disease disease (MMSE < or = 12) for up to six months. Int J Clin Pract. 2002. 56:509–514.

18. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982. 139:1136–1139.

19. Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer's disease. 1999. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;245–246.

20. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA. 2000. 283:1007–1001.

21. Pike CJ. Estrogen modulates bcl-xL expression and beta-amyloid-induced apoptosis. J Neurochem. 1999. 72:1552–1563.

22. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al. Evidence-based dementia practice. 2002. Oxford: Blackwell.

23. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, et al. L-deprenyl in Alzheimer's disease:cognitive and behavioral effects. Neurology. 1998. 50:660–668.

24. Watts RL, Koller WC. Movement disorders. 1997. McGraw-Hill;168–169.

25. Agnoli A, Martucci N, Fabbirini G, Buckley A, Fioravanti M. Monoamine oxidase and dementia : treatment with an inhibitor of MAO-B activity. Demetia. 1990. 109–114.

26. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997. 336:1216–1222.

27. Wieraszko A, Li G, Kornecki E, Hogan MV, Ehrlich YH. Long-term potentiation in hippocampus induced by platelet-activating factor. Neuron. 1993. 10:553–557.

28. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion. Neurology. 1996. 46:1775–1776.

29. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia : a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996. 8:Suppl 3. 497–500.

30. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982. 248(3):333–335.

31. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia:a randomized, double-blind trial. J Clin Psychiatry. 1999. 60(2):107–115.

32. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999. 53(5):946–955.

33. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. The HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities:a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000. 57(10):968–976.

34. Street JS, Clark WS, Kadam DL, Miltan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer dementia. Int J Geriatr Psychiatry. 2001. 16:Suppl 1. S62–S70.

35. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer's disease patients . Alzheimer Dis Assoc Disord. 2002. 16(2):128–130.

36. Ballard CG, O'Brien J, James I, Swann A. Dementia:management of behavioural and psychological symptoms. Nord J Psychiatry. 2003. 57(2):159–160.

37. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease : Part II. Treatment. Am Fam Physician. 2002. 65(12):2525–2534.

38. Qizilbash N, Schneider LS. Evidence-based dementia practice. 2002. Oxford: Blackwell;680.

39. American Psychiatric Association. Practice guidelines for the treatment of psychiatric disorders. 2000. Washington DC: APA;108.

40. Holzer JC, Gitelman DR, Price BH. Efficacy of buspirone in the treatment of dementia with aggression. Am J Psychiatry. 1995. 152(5):812.

41. Gottfries CG, Nyth AL. Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann N Y Acad Sci. 1991. 640:276–279.

42. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992. 86(2):138–145.

43. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease : initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry. 2000. 157(10):1686–1689.

44. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998. 13(2):100–108.

45. Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother. 2001. 35(9):1024–1027.

46. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression:an international double-blind, placebo-controlled trial. Br J Psychiatry. 1996. 168(2):149–157.

47. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease:an open-label study. J Geriatr Psychiatry Neurol. 1996. 9(1):1–6.

48. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol. 2002. 25(6):313–317.

49. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 2002. (127):20–36.

50. Petrie WM, Ban TA. Propranolol in organic agitation. Lancet. 1981. 1:324.

51. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behaviour in senile dementia. J Geriatr Psychiatry Neurol. 1988. 1:226–230.

52. Goad DL, Davis CM, Liem P, Fuselier CC, McDormack JR, Olsen KM. The use of selegeline in Alzheimer's patients with behavior problems. J Clin Psychiatry. 1991. 52:342–345.

53. Schneider LS, Pollock VE, Zemansky MF, Gleason RP, Palmer R, Sloane RB. A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatr Psychiatry Neurol. 1991. 4(3):143–148.

54. Lawlor BA, Aisen PS, Green C, Fine E, Schmeidler J. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 1997. 12(3):319–322.

55. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type:results of a 15-month trial. J Am Geriatr Soc. 1993. 41(11):1219–1225.

56. O'Brien MD. How does cerebrovascular disease cause dementia? Dementia. 1994. 5:133–136.

57. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimers Disease (CERAD) part X : neuropathology confirmation of the clinical diagnosis of Alzheimers disease. Neurology. 1995. 45:461–466.

58. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimers disease. The Nun Study. JAMA. 1997. 277:813–817.

59. Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, et al. The effects of additional pathology on the cognitive deficit in Alzheimer's disease. J Neuropathol Exp Neurol. 1997. 56:165–170.

60. Forette F, Seux M-L, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998. 352:1347–1351.

61. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia : a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol. 2001. 8:361–362.

62. Erkinjuntti T, Kurtz A, Gauthier S, Bullock R, Lillenfield S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease:a randomised trial. Lancet. 2002. 359:1283–1290.

63. Pratt R, Perdomo CA. The Donepezil Study Group. Results of clinical studies with donepezil in vascular dementia. Am J Geriatr Psychiatry. 2002. 10:S. 88–89.

64. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet. 1984. 2:1262–1265.

65. Korczyn AD. Dementia in Parkinson's disease. J Neurol. 2001. 248:S3. 1–4.

66. Kurlan R, Richard IH, Papka M, Marchall F. Movement disorders in Alzheimer's disease : More rigidity of definitions is needed. Mov Disord. 2000. 15(1):24–29.

67. Wragg RE, Jeste DV. Overview of depression andpsychosis in Alzheimer's disease. Am J Psychiatry. 1989. 146:577–587.

68. Burns A. Katona C, Levy R, editors. Psychosis in dementia of the Alzheimer type. Delusions and Hallucinations in Old age. London: Gaskell;228–242. Royal college of psychiatrists.

69. Devanand DP. Gauthier S, Cummings JL, editors. Depression in dementia. Alzheimer's disease and related disorders annual. 2001. London: Martin Dunitz;97–123.

70. McAllister TW. Overview:pseudodementia. Am J Psychiatry. 1983. 140:528–533.

71. Reding MJ, Haycox J, Wigforss K, Brush D, Blass JP. Follow up of patients referred to a dementia service. J Am Geriatr Soc. 1984. 32:265–268.

72. Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Head trauma as a risk factor for Alzheimer's disease:a collaborative re-analysis of case-control studies. Int J Epidemiol. 1991. 20:S28–S35.

73. Mayeux R, Ottman R, Maestre G, Ngai T, Tang MX, Ginsberg H, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology. 1995. 45:555–557.

74. Joyce E. O'Brien J, Ames D, Burns A, editors. Dementia associated with alcoholism. Dementia. 2000. 2nd ed. London: Arnold;799–811.

75. Victor M, Adams RD. Vinken PJ, Bruyn GW, Klawans HL, editors. The alcoholic dementias. Handbook of clinical neurology, Vol 2. Amsterdam: Elsevier Science Pubilishers;335–352.

76. Sachdev P, Trollor J, Looi JCL. Qizilbash N, Schneider LS, Chui H, editors. Alcohol-related dementia. Evidence-based dementia practice. Malden: Blackwell Science Ltd;620–621.